한글목차

일본의 SaMD(Software as a Medical Device) 시장 규모는 2024년 1,955만 달러에서 2033년에는 9,620만 달러에 달할 것으로 예상되며, 예측 기간인 2025-2033년에는 17.3%의 CAGR로 성장할 것으로 예상됩니다.

SaMD(Software as a Medical Device)는 의료 목적으로 설계되어 질병 진단, 치료 권장, 환자 모니터링 및 임상 의사 결정을 가능하게 합니다. SaMD는 AI, 머신러닝, 클라우드 컴퓨팅과 같은 첨단 기술을 활용하여 의료 서비스 제공과 환자 결과를 개선하며, 스마트폰, 태블릿, 클라우드 기반 시스템 등 다양한 플랫폼에서 독립적으로 작동하기 때문에 접근성이 뛰어나고 확장성이 뛰어납니다.

시장 역학

촉진요인과 억제요인

의료 분야에서 클라우드 컴퓨팅과 IoT의 통합 확대

일본의 SaMD(Software as a Medical Device) 시장은 클라우드 컴퓨팅과 IoT의 통합으로 크게 변화하고 있습니다. 클라우드 기반 플랫폼은 의료 데이터의 안전한 저장, 실시간 액세스, 고급 분석 기능을 제공하여 효율성과 의사결정을 개선하고, IoT 디바이스는 환자의 지속적인 모니터링, 원격 진단, 질병 조기 발견, 병원 방문 횟수 감소, 환자 결과 개선 등을 가능케 합니다. 클라우드 컴퓨팅과 IoT의 시너지는 혁신을 가속화하고, 시장 기회를 확대하며, 의료 접근성을 향상시키고 있습니다.

고령 환자 및 의료진의 제한된 디지털 문해력

일본의 SaMD(Software as a Medical Device) 솔루션 채택은 고령 환자 및 의료진의 제한된 디지털 문해력으로 인한 도전에 직면해 있습니다. 고령화 사회는 디지털 건강 애플리케이션을 사용하는 데 어려움을 겪고 있으며, 원격 모니터링 및 AI 진단의 이점을 제한하고 있습니다. 또한, 기존 의료 서비스 제공자들은 SaMD 툴을 워크플로우에 통합하는 데 어려움을 겪을 수 있습니다. 이러한 디지털 기술 숙련도 부족은 신기술에 대한 저항, 부적절한 소프트웨어 사용, 디지털 의료 솔루션에 대한 신뢰 저하로 이어져 시장 성장을 둔화시킬 수 있습니다.

일본의 SaMD(Software as a Medical Device) 시장에 대해 조사했으며, 시장 역학, 지역 및 부문 분석, 경쟁 상황, 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 시장 소개와 범위

제2장 경영진 인사이트와 중요 사항

• 시장 하이라이트와 전략적 중요 사항
• 주요 동향과 향후 예측
• 발췌 : 용도별
• 발췌 : 적응증별

제3장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 의료의 클라우드 컴퓨팅과 IoT의 통합 확대
    • 클라우드 컴퓨팅의 진보
  • 성장 억제요인
    • 고령 환자나 의료종사자의 한정된 디지털 리터러시
    • 지원적인 규제 프레임워크
  • 기회
    • 헬스테크 스타트업에 대한 투자 증가
  • 영향 분석

제4장 전략적 인사이트와 산업 전망

• 시장 리더와 파이오니어
  • 신흥 파이오니어와 저명 기업
  • 확립된 리더와 최대 매출을 보유한 브랜드
  • 시장 리더와 확립된 제품
• CXO의 견해
• 최신 발전과 혁신
• 사례 연구/진행중인 연구
• 규제와 상환 상황
• Porter's Five Forces 분석
• 공급망 분석
• SWOT 분석
• 미충족 수요와 격차
• 시장 진입 및 확장을 위한 권장 전략
• 시나리오 분석 : 베스트 케이스, 기본 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• KOL(Key Opinion Leader)

제5장 용도별

• 질병 관리
• 진단
• 치료 모니터링
• 예측 건강 분석
• 기타

제6장 적응증별

• 당뇨병
• 정신건강
• 종양
• 심혈관
• 호흡기질환
• 기타

제7장 경쟁 구도와 시장 포지셔닝

• 경쟁 구도 개요와 주요 시장 기업
• 시장 점유율 분석과 포지셔닝 매트릭스
• 전략적 파트너십, 인수합병
• 제품 포트폴리오와 혁신의 주요 발전
• 기업 벤치마크

제8장 기업 개요

• Japan Medical Device Corporation
• Nipro Corporation
• Micron, Inc
• Olympus Medical Systems
• Anaut Inc

제9장 가정과 조사 방법

제10장 부록

영문목차

The Japan software as a medical device market reached US$ 19.55 million in 2024 and is expected to reach US$ 96.20 million by 2033, growing at a CAGR of 17.3% during the forecast period 2025-2033.

Software as a Medical Device (SaMD) is designed for medical purposes, enabling disease diagnosis, treatment recommendations, patient monitoring, and clinical decision-making. It uses advanced technologies like AI, machine learning, and cloud computing to improve healthcare delivery and patient outcomes. SaMD operates independently on platforms like smartphones, tablets, or cloud-based systems, making it highly accessible and scalable.

Market Dynamics: Drivers & Restraints

Increasing Integration of Cloud Computing and the Internet of Things (IoT) in Healthcare

Japan's Software as a Medical Device (SaMD) market is being significantly transformed by the integration of cloud computing and IoT. Cloud-based platforms offer secure storage, real-time access, and advanced analytics for medical data, improving efficiency and decision-making. IoT devices enable continuous patient monitoring, remote diagnostics, and early disease detection, reducing hospital visits and improving patient outcomes. The synergy between cloud computing and IoT is accelerating innovation, expanding market opportunities, and improving healthcare accessibility.

Limited Digital Literacy Among Elderly Patients and Healthcare Professionals

The adoption of Software as a Medical Device (SaMD) solution in Japan faces challenges due to limited digital literacy among elderly patients and healthcare professionals. The aging population struggles with digital health applications, limiting the benefits of remote monitoring and AI-driven diagnostics. Traditional healthcare providers may also struggle to integrate SaMD tools into their workflows. This lack of digital proficiency can lead to resistance to new technologies, improper software utilization, and reduced trust in digital healthcare solutions, slowing the market's growth.

Segment Analysis

The Japan software as a medical device market is segmented based on application and indication.

Application:

The diagnostics from application segment is expected to dominate the software as a medical device market with the highest market share

Diagnostics is the process of identifying diseases, conditions, or medical abnormalities through various tests, assessments, and analyses. It includes imaging, laboratory testing, and clinical evaluations. Advancements in digital health now include AI-driven and software-based solutions, enhancing accuracy and efficiency. Effective diagnostics are crucial for preventive care, early intervention, and improving patient outcomes, guiding treatment decisions.

The diagnostics segment in this market is driven by the need for early disease detection, chronic conditions, AI-driven imaging, and data analytics. Remote diagnostics and telemedicine expansion improve healthcare accessibility. Regulatory approvals for AI-powered tools and cloud-based platforms support market growth.

The demand for cost-effective, accurate diagnostic solutions is driving SaMD adoption in precision medicine and personalized healthcare. Several companies are forming strategic partnerships to expand their diagnostic businesses. For instance, in January 2025, Monitor Corporation, a Korean medical AI company, partnered with Japanese digital healthcare provider Doctor-NET to sell its lung cancer diagnosis software in Japan. The AI-powered tool, MONCAD CTLN, aids radiologists in detecting lung cancer using chest CT scans. Doctor-NET has obtained manufacturing and sales certification for the software in Japan.

Competitive Landscape

The major Japan players in the software as a medical device market include Japan Medical Device Corporation, Nipro Corporation, Micron, Inc., Olympus Medical Systems and Anaut Inc. among others.

Key Developments

• In May 2024, Anaut Inc., a surgical support software developer, received regulatory approval for its innovative medical device, "Eureka a," from the Ministry of Health, Labour and Welfare in Japan. The device, designed with advanced artificial intelligence, is set to revolutionize surgical practices.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan software as a medical device market report delivers a detailed analysis with 70 key tables, more than 65 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Application
• 2.4. Snippet by Indication

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Integration of Cloud Computing and the Internet of Things (IoT) In Healthcare
    • 3.1.1.2. Advancements in Cloud Computing
  • 3.1.2. Restraints
    • 3.1.2.1. Limited Digital Literacy Among Elderly Patients and Healthcare Professionals
    • 3.1.2.2. Supportive Regulatory Framework
  • 3.1.3. Opportunity
    • 3.1.3.1. Increased Investment in HealthTech Startups
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with largest selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. SWOT Analysis
• 4.9. Unmet Needs and Gaps
• 4.10. Recommended Strategies for Market Entry and Expansion
• 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.12. Pricing Analysis and Price Dynamics
• 4.13. Key Opinion Leaders

5. By Application

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 5.1.2. Market Attractiveness Index, By Application
• 5.2. Disease Management*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 5.3. Diagnostics
• 5.4. Treatment Monitoring
• 5.5. Predictive Health Analytics
• 5.6. Others

6. By Indication

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 6.1.2. Market Attractiveness Index, By Indication
• 6.2. Diabetes*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Mental Health
• 6.4. Oncology
• 6.5. Cardiovascular
• 6.6. Respiratory Conditions
• 6.7. Others

7. Competitive Landscape and Market Positioning

• 7.1. Competitive Overview and Key Market Players
• 7.2. Market Share Analysis and Positioning Matrix
• 7.3. Strategic Partnerships, Mergers & Acquisitions
• 7.4. Key Developments in Product Portfolios and Innovations
• 7.5. Company Benchmarking

8. Company Profiles

• 8.1. Japan Medical Device Corporation*
  • 8.1.1. Company Overview
  • 8.1.2. Product Portfolio
    • 8.1.2.1. Product Description
    • 8.1.2.2. Product Key Performance Indicators (KPIs)
    • 8.1.2.3. Historic and Forecasted Product Sales
    • 8.1.2.4. Product Sales Volume
  • 8.1.3. Financial Overview
    • 8.1.3.1. Company Revenue's
    • 8.1.3.2. Geographical Revenue Shares
    • 8.1.3.3. Revenue Forecasts
  • 8.1.4. Key Developments
    • 8.1.4.1. Mergers & Acquisitions
    • 8.1.4.2. Key Product Development Activities
    • 8.1.4.3. Regulatory Approvals, etc.
  • 8.1.5. SWOT Analysis
• 8.2. Nipro Corporation
• 8.3. Micron, Inc
• 8.4. Olympus Medical Systems
• 8.5. Anaut Inc

LIST NOT EXHAUSTIVE

9. Assumption and Research Methodology

• 9.1. Data Collection Methods
• 9.2. Data Triangulation
• 9.3. Forecasting Techniques
• 9.4. Data Verification and Validation

10. Appendix

• 10.1. About Us and Services
• 10.2. Contact Us